Article Information
History
- January 10, 2022.
Article Versions
- You are currently viewing Version 1 of this article (January 10, 2022 - 16:00).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Bas Kolen1,2,*,
- Laurens Znidarsic1,
- Andreas Voss3,4,
- Simon Donders5,
- Iris Kamphorst5,
- Maarten van Rijn5,
- Dimitri Bonthuis6,
- Merit Cloquet6,
- Maarten Schram6,
- Rutger Scharloo6,
- Tim Boersma6,
- Tim Stobernack3 and
- Pieter van Gelder1
- 1Delft University of Technology, Delft, The Netherlands
- 2HKV lijn in water, Lelystad, The Netherlands
- 3Radboudumc, Nijmegen, The Netherlands
- 4Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
- 5Breda University of Applied Sciences, Breda, The Netherlands
- 6Fieldlab Program Committee, Zaandam, The Netherlands
- ↵*Corresponding author:
Bas Kolen, Address for correspondence: Bas Kolen, HKV Consultants, Botter 11-29, 8203 AC Lelystad, the Netherlands; email: b.kolen{at}hkv.nl
Posted January 10, 2022.
SARS-CoV-2 risk taxation model and validation based on large scale Dutch test-events
